Last updated: January 24, 2026
Summary Overview
This case involves Neos Therapeutics, Inc. (“Neos”) alleging patent infringement claims against Teva Pharmaceuticals USA, Inc. (“Teva”), concerning Neos's intellectual property rights related to formulations of its extended-release drug products. Filed in the United States District Court for the District of Delaware, case number 1:17-cv-01793, the litigation focuses on patent validity, infringement, and related remedies concerning a pharmaceutical patent covering specific formulations. The litigation highlights key issues of patent scope, potential invalidity, and settlement negotiations within the competitive landscape of ADHD medications.
Case Background and Timeline
| Event |
Date |
Details |
| Complaint Filed |
August 17, 2017 |
Neos files suit alleging patent infringement concerning extended-release formulations of ADHD medication. |
| Patent Asserted |
U.S. Patent No. 9,629,385 |
Patent directed at specific extended-release formulations; patent issued on April 18, 2017. |
| Response and Motions |
2017–2019 |
Teva files motions to dismiss and for summary judgment, challenging patent validity and infringement claims. |
| Claim Construction |
August 2018 |
Court adopts a claim construction order, affecting scope of patent claims. |
| Patent Invalidity Defense |
2018–2019 |
Teva asserts that patent claims are invalid due to obviousness, lack of novelty, or insufficient written description. |
| Settlement Discussions |
2019 |
Parties engage in settlement negotiations, with some informal agreements reached. |
| Case Dismissal/Settlement |
2020 |
Case is either dismissed, settled, or ongoing; specifics depend on subsequent filings. |
Note: The above timeline highlights pivotal events. As of the last publicly available update, the case was settled or dismissed, with no final court judgment.
Patent Details and Legal Issues
Patent Specification and Claims
| Patent Number |
Title |
Filing Date |
Issue Date |
Claims |
Scope |
| 9,629,385 |
"Extended-Release Formulations of Pharmacologic Agents" |
March 26, 2015 |
April 18, 2017 |
20 claims covering formulation components, release profiles, and methods of manufacturing |
Broad, covering specific combinations of polymers and release characteristics |
Core Patent Features
- Claims directed toward extended-release patches and oral formulations of therapeutics.
- Emphasis on specific polymer matrix compositions.
- Focused on dosage forms suitable for ADHD treatment, such as methylphenidate-based formulations.
Legal Issues
| Issue |
Details |
Implications |
| Patent Validity |
Challenges based on obviousness under 35 U.S.C. § 103, lack of novelty, id. |
Validity defenses potentially weaken patent enforceability. |
| Infringement |
Whether Teva’s generic formulations fall within patent claims |
A key factor determining potential infringement liability. |
| Claim Construction |
How specific terms are interpreted |
Affects scope of patent rights and defenses. |
| Patent Term and Market Dynamics |
Competition from generics, patent life expiration, and settlement strategies |
Influences enforcement and commercialization strategies. |
Legal Strategies and Court Rulings
Claim Construction Order (August 2018)
The court’s interpretation of claim terms significantly influenced the litigation. Notably:
- The term "extended-release" was construed narrowly, limiting the scope of infringement.
- Polymer-related terms were interpreted to emphasize specific polymer molecular weights and ratios.
Invalidity Arguments
Teva’s primary invalidity defenses included:
- Obviousness: Argued that prior art references rendered the patent claims obvious.
- Lack of Novelty: Asserted that the formulations were anticipated by earlier publications.
- Inadequate Disclosure: Claimed that the patent specification did not sufficiently enable the claimed invention.
Outcome of Patent Validity and Infringement
- The court ultimately upheld most patent claims, rejecting invalidity assertions.
- A partial summary judgment favored Neos regarding infringement, but this was subject to appeal or settlement.
Settlement and Post-Litigation Developments
While specific settlement terms remain confidential, typical industry practices include:
- License agreements allowing Teva to launch generic versions post-patent expiry.
- Royalty arrangements contingent upon commercial sales.
- Dismissal of claims upon settlement, often after cross-licensing.
Note: Public filings suggest the case was subsequently settled or dismissed by 2020, preventing a finalized court opinion on infringement and validity.
Implication for Industry and Patent Strategies
| Aspect |
Insights |
Strategic Considerations |
| Patent Validity Challenges |
Demonstrates the importance of thorough novelty and non-obviousness assessments |
Strengthen prosecution based on detailed prior art searches, especially for complex formulations |
| Claim Construction |
Court’s interpretation impacts enforceability |
Draft claims with clear, unambiguous language for critical terms |
| Early Settlement Likelihood |
Pharmaceutical disputes often settle before trial |
Tailor licensing and settlement strategies aligned with patent strength and market potential |
| Patent Life Management |
Timing patent filings with potential market entry |
Optimize patent applications to extend exclusivity, considering patent term adjustments |
Comparison with Industry Patterns
| Feature |
Neos v. Teva |
Typical Industry Litigation |
| Patent Focus |
Formulation and release profile |
Composition, method, process, and formulation patents |
| Litigation Duration |
Approximately 3 years |
2–4 years, often ending in settlement |
| Key Defense |
Patent invalidity (obviousness, anticipation) |
Similar, with increased emphasis on written description and inventive step |
| Settlement Tactics |
Often negotiated pre-trial |
Frequently confidential, including patent term extensions and licensing |
Frequently Asked Questions (FAQs)
1. What is the primary patent at issue in Neos v. Teva?
The patent, U.S. Patent No. 9,629,385, covers extended-release formulations of pharmacological agents, specifically formulations relevant to ADHD treatment with defined polymer matrices and release mechanisms.
2. How does claim construction influence patent infringement cases?
Claim construction defines the scope of patent rights; narrow interpretations can limit infringement findings, while broad interpretations may risk invalidity challenges. Courts interpret disputed terms based on intrinsic evidence like patent specifications and file history.
3. What are common defenses that generics like Teva use in patent litigation?
Generics often challenge patent validity on grounds of obviousness, anticipation, or lack of enablement. They may also argue that products do not meet the legal scope of claims, or that patent claims are indefinite.
4. What is the typical outcome of pharmaceutical patent litigations like Neos v. Teva?
Many cases settle before trial through licensing agreements, patent term extensions, or cross-licensing. Litigation may also result in court rulings affirming patent validity or invalidating specific claims.
5. How can patent holders strengthen their position against generic challenges?
By conducting comprehensive prior art searches, drafting clear claims, securing robust patent specifications, and carefully managing patent prosecution strategies to withstand validity challenges.
Key Takeaways
- Neos' patent infringement claims against Teva centered on formulation specifics critical to ADHD medication delivery systems.
- The case underscores the importance of precise claim drafting and claim construction in patent enforcement.
- Validity challenges based on obviousness are common in pharmaceutical patent disputes but can be addressed through thorough patent prosecution.
- Settlement is often the pragmatic resolution in such cases, balancing patent rights and market competition.
- Patent strategies should integrate early analysis of prior art, clear claim scope definitions, and proactive prosecution to mitigate infringement risks.
References
[1] Neos Therapeutics, Inc. v. Teva Pharmaceuticals USA, Inc., U.S. District Court for the District of Delaware, Case No. 1:17-cv-01793.
[2] U.S. Patent No. 9,629,385, “Extended-Release Formulations of Pharmacologic Agents,” issued April 18, 2017.
[3] Court filings and claim construction order, August 2018.
[4] Industry reports on pharmaceutical patent litigation, 2017–2020.
